Compare iShares MSCI South Africa ETF (EZA) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs Smith & Nephew plc — how do they compare? iShares MSCI South Africa ETF trades at $68.99, while Smith & Nephew plc trades at $30.05 (market cap $12.50B). The key difference: Smith & Nephew plc pays a 2.64% dividend while iShares MSCI South Africa ETF pays none, and iShares MSCI South Africa ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| EZA | SNN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $38.70 |
52-Week Low | $56.57 | $28.73 |
Market Cap | — | $12.50B |
Enterprise Value | — | $15.53B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA trades at $69.65, up 4.14% today, with a bullish technical signal from moving averages but overbought oscillators. The stock faces resistance near $68 and support at $66. Recent news highlights macroeconomic pressures on its South African-focused portfolio, including exposure to gold, banking, and platinum group metals amid rising interest rates and inflation.
The outlook is mixed, with technical strength offset by fundamental headwinds from global reflation. Investment opportunities hinge on commodity price stability, while risks include yield curve dynamics and cost of capital increases that may pressure constituent earnings.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
